Veteran pharmaceutical executive Jean-Pierre Garnier to lead Board as BioAge progresses metabolic disease pipeline.
BioAge Labs, Inc, a clinical-stage biopharmaceutical company focusing on metabolic diseases through the lens of human aging, has announced the appointment of Jean-Pierre Garnier, PhD, as the new Chair of its Board of Directors. This strategic decision will raise speculation that the company may be positioning itself for an initial public offering (IPO), a move that would significantly increase its visibility and market impact. Garnier, a former Chief Executive Officer of GlaxoSmithKline (GSK), brings to BioAge decades of leadership experience in the pharmaceutical industry – a critical asset as the company advances its late-stage clinical programs and prepares for potential expansion.
Kristen Fortney, PhD, CEO and co-founder of BioAge, emphasized the significance of this appointment. “We are excited to welcome JP to BioAge’s Board of Directors as Chair,” she said. “His extensive experience in leading biotech and pharmaceutical companies through critical growth phases will be invaluable as we progress our lead compound, azelaprag, through clinical development for obesity and advance our pipeline of metabolic aging therapies.”
Fortney also took the opportunity to acknowledge the contributions of outgoing Chair James Healy, MD, PhD, who will remain on the Board as a Director.
“I would also like to express our deep gratitude to Jim, whose leadership as Chair has been pivotal during a crucial period of growth for BioAge,” she said. “We are pleased that he will continue to contribute his expertise in clinical development and drug strategy as a key member of our Board.”
Garnier’s appointment comes at a time when BioAge is gaining traction in the field of metabolic diseases, an area of increasing interest as the global obesity epidemic continues to grow. The company’s lead product, azelaprag, is an orally administered small molecule agonist of the APJ receptor, which has shown promise in early clinical trials by promoting metabolism and preventing muscle atrophy. A Phase 2 trial of azelaprag, in combination with tirzepatide for obesity treatment, was initiated in mid-2024, with hopes that this therapy could amplify weight loss and improve body composition in patients already receiving incretin-based therapies.
The company’s efforts extend beyond azelaprag; BioAge’s research pipeline also includes orally available small molecule inhibitors targeting NLRP3, a key driver of neuroinflammation, positioning the company as a potential leader in addressing age-related metabolic and neurological diseases. By leveraging human longevity data, BioAge has developed a platform that offers novel insights into the biology of aging – insights that underpin the company’s pipeline of preclinical programs.
Garnier, whose career in the pharmaceutical industry spans several decades, served as CEO of GSK from 2000 to 2008, where he played a pivotal role in the merger between Glaxo Wellcome and SmithKline Beecham. He has also held senior executive positions at SmithKline Beecham and Schering-Plough. His board experience is extensive, having served as Chairman of Actelion, which was acquired by Johnson & Johnson in 2017 for $30 billion, as well as holding non-executive Chair positions at Alzheon, Idorsia and Carmat. Garnier is currently the Chairman of Cellectis SA and sits on the Board of Directors for Carrier Global Corporation. He also brings a distinguished academic background, with a PhD in pharmacology from Louis Pasteur University and an MBA from Stanford University; his achievements have been recognized through honors such as the Knight Commander of the Order of the British Empire and the Officier de la Légion d’Honneur.
Commenting on his new role, Garnier expressed enthusiasm for the company’s direction: “This is a transformative era for the treatment of obesity and cardiometabolic diseases, and I’m excited to support BioAge as it leads the way with innovative approaches that could reshape the future of patient care,” he said. “I look forward to working alongside Kristen and BioAge’s talented leadership team to fully realize the potential of azelaprag and advance the company’s earlier stage pipeline to address diseases that limit healthspan for large patient populations.” Garnier’s remarks reflect an optimism not only for BioAge’s current trajectory but also for the wider potential impact of its therapeutic candidates that could extend both healthspan and lifespan.
James Healy, who has guided BioAge through a crucial period of growth and transformation, commented: “It has been a privilege to serve as Chair of BioAge’s Board of Directors and lay the foundation for the company’s transformation as a late-stage clinical company. I look forward to continuing on BioAge’s Board as a Director while lending my full support to JP in his new role.” Healy’s ongoing involvement ensures continuity of leadership during what is likely to be a critical period in BioAge’s evolution.
The appointment of Garnier also hints at larger strategic moves for BioAge as it continues to evolve from a clinical-stage biotech into a more mature entity, potentially setting the stage for an IPO. Such a move would not be unprecedented for a company at this stage in its development, particularly as BioAge builds momentum with its promising clinical programs and continues to refine its approach to metabolic aging therapies.
As BioAge progresses through this new phase of leadership under Garnier, the company’s focus on treating metabolic diseases by targeting the biology of aging remains clear. Azelaprag and the company’s broader pipeline represent opportunities to address significant unmet needs in patient care – especially in aging populations where metabolic conditions often compound other health issues. Should BioAge continue to demonstrate clinical success, its potential in the biopharmaceutical space could be considerable; for now, we imagine that all eyes will be on how BioAge’s leadership team leverages this expertise both to bring new therapies to market and to fuel the company’s growth ambitions.
